Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology

Epizyme (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today its first-in-human data on the effects of EZH2 inhibition in patients with advanced solid tumors and B-cell non-Hodgkin lymphoma (NHL) was published in the peer-reviewed The Lancet Oncology. The objectives of the Phase 1 dose-escalation portion of the study were to evaluate the safety and tolerability of orally dosed tazemetostat, a first-in-class selective inhibitor of EZH2. The study established the recommended dose for the Phase 2 expansion study and demonstrated favorable safety findings and anti-tumor activity.

As quoted in the press release:

“Today’s publication in The Lancet Oncology reports the safety and tolerability endpoints for tazemetostat in this study, which enabled further evaluation of EZH2 inhibition in INI1- and SMARCA4-negative solid tumors and NHL,” said Professor Antoine Italiano, MD, Ph.D. of Institut Bergonie and lead author of the paper. “I’m also encouraged by the preliminary anti-tumor activity observed in this study.”

Click here to read the full press release.